Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers

Pharmacotherapy
Desiree L TomiloGene D Morse

Abstract

To determine whether the pharmacokinetics of atazanavir, a protease inhibitor used to treat human immunodeficiency virus (HIV) infection, are altered by its coadministration with lansoprazole, a proton pump inhibitor. Single-dose, open-label, complete-crossover study. Clinical research center. Ten healthy adult volunteers. In phase A, subjects received a single oral dose of atazanavir 400 mg alone. In phase B, the same subjects received oral lansoprazole 60 mg, and after 24 hours they were given a second dose of oral lansoprazole 60 mg with atazanavir 400 mg. Eleven blood samples were collected from each subject over a 24-hour period for determination of atazanavir plasma concentrations by a validated high-performance liquid chromatography assay. Pharmacokinetic analysis was performed by standard noncompartmental methods. Nine subjects completed the study, and no significant adverse events were reported. Absorption of atazanavir was significantly reduced when it was coadministered with lansoprazole, as evidenced by a 94% decline in mean area under the concentration-time curve during the 24 hours after administration (AUC(0-24)) (p<0.01). The mean +/- SD AUC(0-24) for phase A was 16.3 +/- 9.0 microM x hour versus 0.95 +/- 1.8 mi...Continue Reading

References

Nov 3, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M J SheltonG D Morse
Aug 23, 2001·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·T T DoanW J Pan
Dec 12, 2001·Clinical Pharmacokinetics·P F SmithG D Morse
Feb 5, 2002·Expert Opinion on Pharmacotherapy·D A Gremse
Mar 6, 2003·Journal of Clinical Pharmacology·Mark J SheltonGene D Morse
Aug 9, 2003·Drugs·David R Goldsmith, Caroline M Perry
Nov 1, 1993·British Journal of Clinical Pharmacology·Z HusseinJ I Isenberg
May 15, 2004·Alimentary Pharmacology & Therapeutics·J W FrestonC Q Lee
Jan 7, 2005·Clinical Pharmacokinetics·Patrick F SmithGene D Morse
Apr 2, 2005·AIDS·Bradley W KoselAnn C Collier

❮ Previous
Next ❯

Citations

Aug 6, 2008·European Journal of Clinical Pharmacology·Shaojun Shi, Ulrich Klotz
Sep 9, 2008·The Journal of Antimicrobial Chemotherapy·Giovanni GuaraldiRoberto Esposito
Dec 5, 2008·Journal of Gastroenterology and Hepatology·Ana Luiza Werneck-Silva, Ivete Bedin Prado
Jan 16, 2008·Clinical Pharmacokinetics·Ronald W Falcon, Thomas N Kakuda
Jul 9, 2010·Clinical Pharmacokinetics·Ryuichi Ogawa, Hirotoshi Echizen
Sep 29, 2011·Drugs·Ryuichi Ogawa, Hirotoshi Echizen
Feb 20, 2014·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Ralph-Steven Wedemeyer, Henning Blume
Dec 5, 2008·Expert Review of Anti-infective Therapy·Robin Wood
Mar 23, 2007·Expert Opinion on Pharmacotherapy·María Jesús Pérez-Elías
Jun 25, 2009·Expert Opinion on Investigational Drugs·Lucy Garvey, Alan Winston
Oct 30, 2009·Expert Opinion on Drug Metabolism & Toxicology·Danièle Bentué-FerrerEric Bellissant
Apr 13, 2007·Expert Opinion on Drug Metabolism & Toxicology·Sarah M McCabeGene D Morse
Apr 18, 2009·Journal of Pharmaceutical Sciences·Joachim BrouwersPatrick Augustijns
Aug 9, 2011·Thérapie·Caroline SolasUNKNOWN Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique
Mar 24, 2009·Alimentary Pharmacology & Therapeutics·E LahnerG Delle Fave
Sep 23, 2014·Chemistry & Biology·Bradley Croy DoakJan Kihlberg
Jun 4, 2015·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Andrew StolbachPaul Pham
May 12, 2015·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Ajay SaxenaSridhar Desikan
Jul 10, 2013·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·Rachel TitusMary F Otterson
Nov 2, 2006·The Annals of Pharmacotherapy·Patricia Pecora FulcoGonzalo M L Bearman
Aug 1, 2018·The Journal of Pharmacy and Pharmacology·Chara LitouJennifer B Dressman
Jan 17, 2012·Scandinavian Journal of Gastroenterology·Lars AgréusJoseph Sung
Nov 9, 2019·Current Drug Metabolism·Miantezila Basilua JoePochart Philippe
Jul 23, 2019·Expert Opinion on Drug Delivery·Yuqing GongSantosh Kumar
Apr 12, 2019·Drugs·Evan Elias, Laura E Targownik
Sep 14, 2006·The Annals of Pharmacotherapy·Eric G Sahloff, Joan M Duggan
Dec 7, 2007·Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria·P AmarilesM J Faus

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.